CN106361775B - 一种成年女性营养素及其制作方法 - Google Patents
一种成年女性营养素及其制作方法 Download PDFInfo
- Publication number
- CN106361775B CN106361775B CN201610767486.0A CN201610767486A CN106361775B CN 106361775 B CN106361775 B CN 106361775B CN 201610767486 A CN201610767486 A CN 201610767486A CN 106361775 B CN106361775 B CN 106361775B
- Authority
- CN
- China
- Prior art keywords
- vitamin
- adult female
- nutrient
- raw material
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 229940088594 vitamin Drugs 0.000 claims abstract description 46
- 229930003231 vitamin Natural products 0.000 claims abstract description 46
- 235000013343 vitamin Nutrition 0.000 claims abstract description 46
- 239000011782 vitamin Substances 0.000 claims abstract description 46
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 45
- 239000002994 raw material Substances 0.000 claims abstract description 33
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 32
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 28
- 210000003101 oviduct Anatomy 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 26
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 21
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 16
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims abstract description 16
- 229960001763 zinc sulfate Drugs 0.000 claims abstract description 16
- 229910000368 zinc sulfate Inorganic materials 0.000 claims abstract description 16
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 12
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 12
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 12
- 229920002472 Starch Polymers 0.000 claims abstract description 12
- 239000008103 glucose Substances 0.000 claims abstract description 12
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 12
- 239000008107 starch Substances 0.000 claims abstract description 12
- 235000019698 starch Nutrition 0.000 claims abstract description 12
- 239000011790 ferrous sulphate Substances 0.000 claims abstract description 11
- 235000003891 ferrous sulphate Nutrition 0.000 claims abstract description 11
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims abstract description 11
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims abstract description 11
- -1 oviductus ranae Chemical compound 0.000 claims abstract description 9
- 239000007888 film coating Substances 0.000 claims abstract description 8
- 238000009501 film coating Methods 0.000 claims abstract description 8
- 238000005303 weighing Methods 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 14
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 14
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 13
- 229930182817 methionine Natural products 0.000 claims description 13
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 8
- 229930003268 Vitamin C Natural products 0.000 claims description 8
- 235000019154 vitamin C Nutrition 0.000 claims description 8
- 239000011718 vitamin C Substances 0.000 claims description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 7
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 7
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 7
- 229930003316 Vitamin D Natural products 0.000 claims description 7
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 7
- 229960003512 nicotinic acid Drugs 0.000 claims description 7
- 235000001968 nicotinic acid Nutrition 0.000 claims description 7
- 239000011664 nicotinic acid Substances 0.000 claims description 7
- 229940055726 pantothenic acid Drugs 0.000 claims description 7
- 235000019161 pantothenic acid Nutrition 0.000 claims description 7
- 239000011713 pantothenic acid Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 235000019155 vitamin A Nutrition 0.000 claims description 7
- 239000011719 vitamin A Substances 0.000 claims description 7
- 239000011691 vitamin B1 Substances 0.000 claims description 7
- 239000011715 vitamin B12 Substances 0.000 claims description 7
- 239000011716 vitamin B2 Substances 0.000 claims description 7
- 239000011726 vitamin B6 Substances 0.000 claims description 7
- 235000019166 vitamin D Nutrition 0.000 claims description 7
- 239000011710 vitamin D Substances 0.000 claims description 7
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 7
- 229940045997 vitamin a Drugs 0.000 claims description 7
- 229940046008 vitamin d Drugs 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 235000016709 nutrition Nutrition 0.000 abstract description 5
- 230000035764 nutrition Effects 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 239000013589 supplement Substances 0.000 abstract description 4
- 229920000858 Cyclodextrin Polymers 0.000 abstract description 2
- 239000001116 FEMA 4028 Substances 0.000 abstract description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract description 2
- 229960004853 betadex Drugs 0.000 abstract description 2
- 150000008546 L-methionines Chemical class 0.000 abstract 1
- 229960003563 calcium carbonate Drugs 0.000 abstract 1
- 229960001781 ferrous sulfate Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229960001031 glucose Drugs 0.000 abstract 1
- 238000005469 granulation Methods 0.000 abstract 1
- 230000003179 granulation Effects 0.000 abstract 1
- 229940032147 starch Drugs 0.000 abstract 1
- 239000000047 product Substances 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000007654 immersion Methods 0.000 description 7
- 230000036541 health Effects 0.000 description 6
- 230000002936 tranquilizing effect Effects 0.000 description 6
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000002457 bidirectional effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229940063733 ferrous sulfate 150 mg Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940000252 folic acid 2 mg Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 229940070537 vitamin E 150 mg Drugs 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000191896 Rana sylvatica Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940108967 ferrous sulfate 200 mg Drugs 0.000 description 1
- 229940109005 ferrous sulfate 250 mg Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/65—Amphibians, e.g. toads, frogs, salamanders or newts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供了一种成年女性营养素,由以下原料制成:维生素、β‑环糊精、L‑甲硫氨酸、γ‑氨基丁酸、林蛙油、碳酸钙、硫酸亚铁、硫酸锌、葡萄糖、麦芽糊精和淀粉,配方科学合理,各营养素搭配作用,能够同时参与人体吸收,多重补充成年女性所需营养。本发明还提供了一种成年女性营养素的制作方法,经过称料,微包囊,浸泡,混合,制粒、压片、薄膜包衣制得。
Description
【技术领域】
本发明涉及保健药品领域,具体涉及一种成年女性营养素及其制作方法。
【背景技术】
现代社会竞争激烈,生活节奏加快,工作压力增大,女性大多参加工作,分担经济压力。成年女性在家庭生活和社会工作都扮演了重要的角色,在各个阶段的各种经历对身体健康有一定影响,需要外界食药的调理:妊娠期由于胎儿机体生长,需要补充维生素、叶酸等;生理期由于血液流失,需要补血补气;更年期由于卵巢功能衰竭,会出现神经紊乱、加速衰老等症状,需要适当调理。除了女性特殊的阶段,日常的家务劳动和工作任务也会由于费心费力引起免疫力降低、内分泌失调、失眠紧张等症状。为解决此问题,市场上出现一些女性保健抗衰老产品,但这些产品参差不齐,绝大部分功效单一,效果不明显,其所含营养成分在食品中即可补充,无需购买消费品便可食补。
【发明内容】
本发明所要解决的技术问题是,针对以上现有技术的缺点,提供一种成年女性营养素及其制作方法,能够多重补充成年女性所需营养,双向调节精神活力和镇静安神。
本发明的技术方案是:一种成年女性营养素,由以下含量的原料制成:维生素1~1.5g/kg、β-环糊精1~2g/kg、L-甲硫氨酸30~50mg/kg、γ-氨基丁酸10~30mg/kg、林蛙油10~30g/kg、碳酸钙5~15g/kg、硫酸亚铁100~250mg/kg、硫酸锌100~250mg/kg、葡萄糖100~400g/kg、麦芽糊精50~150g/kg,余量为淀粉。
L-甲硫氨酸,又称蛋氨酸,是人体的八种必需氨基酸之一,需从外界获得,微甜,但有特殊臭味,加水混合过程中,可除去臭味,方便食用。γ-氨基丁酸属神经抑制性氨基酸,具有镇静、催眠、抗惊厥、降血压的生理作用,对女性可美容润肤,延缓脑衰老机能,改善肾机能,活化肝功能,促进人体内氨基酸代谢的平衡,调节免疫功能;同时,γ-氨基丁酸能够与碳酸钙结合,钙离子嫁接到羧基上,成为有机的整体,更利于被人体完全吸收。林蛙油中含有丰富的雌激素、氨基酸、微量干细胞,对机体的生长发育、延缓衰老有较强的促进作用,是女性内分泌调补大师。经水浸泡过的林蛙油变的松软、膨胀,能够溶解硫酸亚铁、硫酸锌,并 且使得铁、锌与其结合,以有机态形式存在,有助于人体吸收而不会以水溶液形式流失。碳酸钙与γ-氨基丁酸结合后,以有机物形式存在,易于人体吸收,而不再是难溶态,防止出现结石。虽然大部分组分比较平常,适宜男女老少等和各类人群,但由于林蛙油和γ-氨基丁酸的添加,此药物更适合成年女性服用:林蛙油可以与硫酸亚铁、硫酸锌结合,大大增加有效成分的吸收率,且可以保持精神活力;而γ-氨基丁酸可以在劳累工作后发挥效用,调节女性疲劳,镇静安神。也就是说,该药物可以根据女性生活工作的状态发挥不同效用,达到双向调节精神活力和镇静安神的效果。采用上述科学合理的配方,该保健药品能够在副作用小、适用人群多的基础上,起到镇静安神,延缓脑衰老,调节女性内分泌的效用。
优选地,一种成年女性营养素,由以下含量的原料制成:维生素1~1.2g/kg、β-环糊精1~1.5g/kg、L-甲硫氨酸30~40mg/kg、γ-氨基丁酸15~25mg/kg、林蛙油15~25g/kg、碳酸钙5~10g/kg、硫酸亚铁100~200mg/kg、硫酸锌100~200mg/kg、葡萄糖200~300g/kg、麦芽糊精50~100g/kg,余量为淀粉。
具体地,一种成年女性营养素,所述维生素由以下含量的原料制成:维生素A 7.5~8mg RE/g、维生素B1 13~15mg/g、维生素B2 13~15mg/g、维生素B6 13~14mg/g、维生素B12 20~25μg/g、维生素C 0.93~0.98g/g、维生素D 40~60μg/g、烟酸10~20mg/kg、叶酸2~6mg/kg、泛酸40~60mg/kg,余量为维生素C。多种维生素适量合理的搭配添加到成年女性营养素中,可补充日常所需营养。β-环糊精可以有效保护维生素的成分不被破坏。
一种成年女性营养素的制作方法,它包括以下步骤:
1)称料:按照上述配比称取原料;
2)微包囊:采用β-环糊精对维生素进行微包囊处理;
3)浸泡:将林蛙油加水浸泡12~14h,至胀发,水洗2-3次,切碎;
4)混合:将除维生素外的原料加水混合,搅拌均匀后干燥3~5h,再加入维生素,得到混合物;
5)成品:将混合物制粒、压片、薄膜包衣。
具体地,所述步骤2)在真空度为0.02~0.1MPa,温度为-10~0℃的条件下进行。维生素在空气中易氧化、分解,在高温下会降解、变色,为保证产品营养素的成分保留完整,需要对维生素预先进行保护处理,即控制真空度为0.02~0.1MPa,温 度为-10~0℃。采用β-环糊精对维生素进行微包囊处理,能够有效的保护维生素成分的活性,延长保质期,增强食用效果。
具体地,所述步骤3)中水的温度为0~15℃。林蛙油虽然营养丰富,但其需要经冷水浸泡膨胀松软之后才能食用。但对不了解此珍贵补品的人群来说,会认为其油腻有害,而拒绝食用。所以将其浸泡处理后混合到营养素中,更有利于人们接受。
具体地,所述步骤4)在20~30℃条件下进行。控制搅拌混合的温度,有利于维持各种营养物的活性成分,延长保质期。
本发明具有以下有益的技术效果:
1)采用科学合理的配方,各营养素搭配作用,能够同时参与人体吸收,多重补充成年女性所需营养,双向调节精神活力和镇静安神;
2)该保健药品副作用小,镇静安神,延缓脑衰老,调节女性内分泌的效用;
3)采用β-环糊精对维生素进行微包囊处理,能够有效的保护维生素成分的活性,延长保质期,增强食用效果;
4)林蛙油经浸泡处理后,溶解硫酸亚铁、硫酸锌,混合到营养素中,更有利于人们接受。
【具体实施方式】
以下结合具体实施例,对本发明做进一步描述。
以下所提供的实施例并非用以限制本发明所涵盖的范围,所描述的步骤也不是用以限制其执行顺序。本领域技术人员结合现有公知常识对本发明做显而易见的改进,亦落入本发明要求的保护范围之内。
实施例一
一种成年女性营养素,它由以下含量的原料制成:维生素1g/kg、β-环糊精1g/kg、L-甲硫氨酸30mg/kg、γ-氨基丁酸10mg/kg、林蛙油10g/kg、碳酸钙5g/kg、硫酸亚铁100mg/kg、硫酸锌100mg/kg、葡萄糖100g/kg、麦芽糊精50g/kg,余量为淀粉。
具体地,所述维生素由以下含量的原料制成:维生素A 7.5mg RE/g、维生素B113mg/g、维生素B2 13mg/g、维生素B6 13mg/g、维生素B12 20μg/g、维生素D 40μg/g、维生素E130mg/g、烟酸10mg/kg、叶酸2mg/kg、泛酸40mg/kg,余 量为维生素C。
一种成年女性营养素的制作方法,它包括以下步骤:
1)称料:按照上述配比称取原料;
2)微包囊:在真空度为0.02MPa,温度为0℃采用β-环糊精对维生素进行微包囊处理;
3)浸泡:将林蛙油加0℃水浸泡14h,至胀发,水洗2次,切碎;
4)混合:在20℃温度下,将除维生素外的原料加水混合,搅拌均匀后干燥3h,再加入维生素,得到混合物;
5)成品:将混合物制粒、压片、薄膜包衣。
实施例二
一种成年女性营养素,它由以下含量的原料制成:维生素1.5g/kg、β-环糊精2g/kg、L-甲硫氨酸50mg/kg、γ-氨基丁酸30mg/kg、林蛙油30g/kg、碳酸钙15g/kg、硫酸亚铁250mg/kg、硫酸锌250mg/kg、葡萄糖400g/kg、麦芽糊精150g/kg,余量为淀粉。
具体地,所述维生素由以下含量的原料制成:维生素A 8mg RE/g、维生素B1 15mg/g、维生素B2 15mg/g、维生素B6 14mg/g、维生素B12 25μg/g、维生素D 60μg/g、维生素E150mg/g、烟酸20mg/kg、叶酸6mg/kg、泛酸60mg/kg,余量为维生素C。
一种成年女性营养素的制作方法,它包括以下步骤:
1)称料:按照上述配比称取原料;
2)微包囊:在真空度为0.1MPa,温度为-10℃采用β-环糊精对维生素进行微包囊处理;
3)浸泡:将林蛙油加15℃水浸泡12h,至胀发,水洗3次,切碎;
4)混合:在30℃温度下,将除维生素外的原料加水混合,搅拌均匀后干燥5h,再加入维生素,得到混合物;
5)成品:将混合物制粒、压片、薄膜包衣。
实施例三
一种成年女性营养素,它由以下含量的原料制成:维生素1g/kg、β-环糊精1g/kg、L-甲硫氨酸30mg/kg、γ-氨基丁酸15mg/kg、林蛙油15g/kg、碳酸钙5g/kg、 硫酸亚铁100mg/kg、硫酸锌100mg/kg、葡萄糖200g/kg、麦芽糊精50g/kg,余量为淀粉。
具体地,所述维生素由以下含量的原料制成:维生素A 7.5mg RE/g、维生素B113mg/g、维生素B2 13mg/g、维生素B6 13mg/g、维生素B12 20μg/g、维生素D 40μg/g、维生素E130mg/g、烟酸10mg/kg、叶酸2mg/kg、泛酸40mg/kg,余量为维生素C。
一种成年女性营养素的制作方法,它包括以下步骤:
1)称料:按照上述配比称取原料;
2)微包囊:在真空度为0.02MPa,温度为0℃采用β-环糊精对维生素进行微包囊处理;
3)浸泡:将林蛙油加0℃水浸泡14h,至胀发,水洗2次,切碎;
4)混合:在20℃温度下,将除维生素外的原料加水混合,搅拌均匀后干燥3h,再加入维生素,得到混合物;
5)成品:将混合物制粒、压片、薄膜包衣。
实施例四
一种成年女性营养素,它由以下含量的原料制成:维生素1.2g/kg、β-环糊精5g/kg、L-甲硫氨酸40mg/kg、γ-氨基丁酸25mg/kg、林蛙油25g/kg、碳酸钙10g/kg、硫酸亚铁200mg/kg、硫酸锌200mg/kg、葡萄糖300g/kg、麦芽糊精100g/kg,余量为淀粉。
具体地,所述维生素由以下含量的原料制成:维生素A 8mg RE/g、维生素B1 15mg/g、维生素B2 15mg/g、维生素B6 14mg/g、维生素B12 25μg/g、维生素D 60μg/g、维生素E150mg/g、烟酸20mg/kg、叶酸6mg/kg、泛酸60mg/kg,余量为维生素C。
一种成年女性营养素的制作方法,它包括以下步骤:
1)称料:按照上述配比称取原料;
2)微包囊:在真空度为0.1MPa,温度为-10℃采用β-环糊精对维生素进行微包囊处理;
3)浸泡:将林蛙油加15℃水浸泡12h,至胀发,水洗3次,切碎;
4)混合:在30℃温度下,将除维生素外的原料加水混合,搅拌均匀后干燥5h, 再加入维生素,得到混合物;
5)成品:将混合物制粒、压片、薄膜包衣。
实施例五
一种成年女性营养素,它由以下含量的原料制成:维生素1.1g/kg、β-环糊精1.5g/kg、L-甲硫氨酸35mg/kg、γ-氨基丁酸20mg/kg、林蛙油20g/kg、碳酸钙8g/kg、硫酸亚铁150mg/kg、硫酸锌150mg/kg、葡萄糖250g/kg、麦芽糊精80g/kg,余量为淀粉。
具体地,所述维生素由以下含量的原料制成:维生素A 7.8mg RE/g、维生素B114mg/g、维生素B2 14mg/g、维生素B6 13.05mg/g、维生素B12 22μg/g、维生素D 50μg/g、维生素E 140mg/g、烟酸15mg/kg、叶酸4mg/kg、泛酸50mg/kg,余量为维生素C。
一种成年女性营养素的制作方法,它包括以下步骤:
1)称料:按照上述配比称取原料;
2)微包囊:在真空度为0.05MPa,温度为-5℃采用β-环糊精对维生素进行微包囊处理;
3)浸泡:将林蛙油加10℃水浸泡13h,至胀发,水洗3次,切碎;
4)混合:在25℃温度下,将除维生素外的原料加水混合,搅拌均匀后干燥4h,再加入维生素,得到混合物;
5)成品:将混合物制粒、压片、薄膜包衣。
对比例一
与实施例五相比,组成林蛙油含量减少一半,即:
一种成年女性营养素,它由以下含量的原料制成:维生素1.1g/kg、β-环糊精1.5g/kg、L-甲硫氨酸35mg/kg、γ-氨基丁酸20mg/kg、林蛙油10g/kg、碳酸钙8g/kg、硫酸亚铁150mg/kg、硫酸锌150mg/kg、葡萄糖250g/kg、麦芽糊精80g/kg,余量为淀粉。
对比例二
与实施例五相比,组成少了林蛙油,即:
一种成年女性营养素,它由以下含量的原料制成:维生素1.1g/kg、β-环糊精1.5g/kg、L-甲硫氨酸35mg/kg、γ-氨基丁酸20mg/kg、碳酸钙8g/kg、硫酸亚铁 150mg/kg、硫酸锌150mg/kg、葡萄糖250g/kg、麦芽糊精80g/kg,余量为淀粉。
以小白鼠不进食,仅服用该药物做临床试验,通过原子吸收法测定服用前后相关参数,血清铁蛋白、血清锌在服用3小时后检测,尿液铁离子和尿液锌离子统计全天,结果如下:
表1:实施例五、对比例一和对比例二林蛙油对吸收的影响比较
从上表可以看出,添加林蛙油后,硫酸亚铁和硫酸锌更容易与其结合,形成血清铁蛋白和血清锌,进而更容易被人体吸收;而未添加林蛙油,服用的铁和锌大部分会以尿液形式排出。
Claims (6)
1.一种成年女性营养素,其特征在于,它由以下含量的原料制成:维生素1~1.5g/kg、β-环糊精1~2g/kg、L-甲硫氨酸30~50mg/kg、γ-氨基丁酸10~30mg/kg、林蛙油10~30g/kg、碳酸钙5~15g/kg、硫酸亚铁100~250mg/kg、硫酸锌100~250mg/kg、葡萄糖100~400g/kg、麦芽糊精50~150g/kg,余量为淀粉;所述维生素由以下含量的原料制成:维生素A 7.5~8mg RE/g、维生素B1 13~15mg/g、维生素B2 13~15mg/g、维生素B6 13~14mg/g、维生素B1220~25μg/g、维生素D 40~60μg/g、维生素E 130~150mg/g、烟酸10~20mg/kg、叶酸2~6mg/kg、泛酸40~60mg/kg,余量为维生素C。
2.根据权利要求1所述的成年女性营养素,其特征在于,它由以下含量的原料制成:维生素1~1.2g/kg、β-环糊精1~1.5g/kg、L-甲硫氨酸30~40mg/kg、γ-氨基丁酸15~25mg/kg、林蛙油15~25g/kg、碳酸钙5~10g/kg、硫酸亚铁100~200mg/kg、硫酸锌100~200mg/kg、葡萄糖200~300g/kg、麦芽糊精50~100g/kg,余量为淀粉。
3.根据权利要求1所述的成年女性营养素的制作方法,其特征在于,它包括以下步骤:
1)称料:按照权利要求1的配比称取原料;
2)微包囊:采用β-环糊精对维生素进行微包囊处理;
3)浸泡:将林蛙油加水浸泡12~14h,至胀发,水洗2-3次,切碎;
4)混合:将除维生素外的原料加水混合,搅拌均匀后干燥3~5h,再加入维生素,得到混合物;
5)成品:将混合物制粒、压片、薄膜包衣。
4.根据权利要求3所述的成年女性营养素的制作方法,其特征在于,所述步骤2)在真空度为0.02~0.1MPa,温度为-10~0℃的条件下进行。
5.根据权利要求3所述的成年女性营养素的制作方法,其特征在于,所述步骤3)中水的温度为0~15℃。
6.根据权利要求3所述的成年女性营养素的制作方法,其特征在于,所述步骤4)在20~30℃条件下进行搅拌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610767486.0A CN106361775B (zh) | 2016-08-29 | 2016-08-29 | 一种成年女性营养素及其制作方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610767486.0A CN106361775B (zh) | 2016-08-29 | 2016-08-29 | 一种成年女性营养素及其制作方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106361775A CN106361775A (zh) | 2017-02-01 |
CN106361775B true CN106361775B (zh) | 2018-02-06 |
Family
ID=57901637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610767486.0A Expired - Fee Related CN106361775B (zh) | 2016-08-29 | 2016-08-29 | 一种成年女性营养素及其制作方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106361775B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114469883A (zh) * | 2020-10-27 | 2022-05-13 | 河北科星药业有限公司 | 一种治疗仔猪坏血症的氨酪酸维生素c片、制备方法和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101810336B (zh) * | 2010-04-30 | 2012-03-21 | 广东仙乐制药有限公司 | 一种咀嚼性软胶囊及其制备方法 |
CN102793163A (zh) * | 2012-07-20 | 2012-11-28 | 惠州市鑫福来实业发展有限公司 | 一种钙铁锌硒多维咀嚼片及其制备方法 |
-
2016
- 2016-08-29 CN CN201610767486.0A patent/CN106361775B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN106361775A (zh) | 2017-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018077312A1 (zh) | 一种增强免疫力的泡腾片及其制备方法 | |
CN105077268B (zh) | 一种含有多种维生素和植物提取物以及微量元素的软胶囊制剂及其制备方法 | |
CN102133392A (zh) | 促进虾蟹蜕壳硬壳和防病抗应激的水体泼洒复合制剂 | |
CN104397825A (zh) | 一种蛋白固体饮料 | |
CN107929313A (zh) | 用于预防和治疗钙缺乏症的天然型牡蛎碳酸钙制剂及其制备方法 | |
CN110558388A (zh) | 一种老年人用的牦牛奶粉配方及其制备方法 | |
CN106306948A (zh) | 一种饮料及其制备方法 | |
CN106361775B (zh) | 一种成年女性营养素及其制作方法 | |
CN107156747A (zh) | 一种虫草核桃肽营养粉及其制备方法 | |
CN106165905A (zh) | 一种钙加维生素软胶囊及制备方法 | |
CN107375322B (zh) | 儿童及青少年型多种维生素矿物质泡腾片及其制备方法 | |
CN107296282A (zh) | 一种钙铁锌硒维生素片的制备方法 | |
CN101623100A (zh) | 一种利用流化床喷涂技术生产营养强化米的方法 | |
CN104431519A (zh) | 妊娠期母羊矿物质饲料添加剂 | |
CN108715785A (zh) | 一种鹿胎盘酒及其制备方法 | |
CN107494746A (zh) | 一种促进骨骼发育的功能性食品及其制备方法 | |
CN107751998A (zh) | 一种用于苯丙酮尿症患者的食用配方粉 | |
CN107647235A (zh) | 一种维生素ad固体饮料及其制备方法 | |
CN107279865A (zh) | 一种玛咖牡蛎食疗产品及其制备方法 | |
CN101331889A (zh) | 一种含有机硒缓释胶囊的硒营养强化小麦粉生产方法 | |
CN109953332A (zh) | 一种玫瑰钙片及其制备方法 | |
CN103931870A (zh) | 一种防治老年痴呆的花生蛋白粉及制备方法 | |
CN108095084A (zh) | 一种大叶藻海参保健食品及其制备方法 | |
EA028698B1 (ru) | Биологически активная добавка к пище | |
CN102048221A (zh) | 一种营养饮料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180206 |